Neumora Therapeutics' shares plunged over 80% on the first trading day of 2025 due to the failure of its depression drug, navacaprant, in a Phase 3 trial. The drug did not show any significant improvement in depressive symptoms compared to a placebo.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing